Previous 10 | Next 10 |
2024-05-08 07:06:13 ET More on AstraZeneca AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca PLC (AZN) Q1 2024 Earnings Call Transcript AstraZeneca invests $140M in Cellectis, raising stake to 44% ...
2024-05-08 06:55:36 ET Summary Ascendis Pharma is expected to achieve cash flow break even by the end of 2024, driven by its core franchise of medicines for rare endocrinology conditions. The company's approved drug, Skytrofa, has shown strong sales and has the potential to be a b...
2024-05-06 13:31:49 ET More on AstraZeneca, Cellectis, etc. AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca PLC (AZN) Q1 2024 Earnings Call Transcript Novo, Teva, AstraZeneca issued FTC warnings over ...
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biote...
2024-05-04 15:30:00 ET Read the full article on Seeking Alpha For further details see: Pharma R&D productivity seen improving for the first time in years - Deloitte
2024-05-03 10:28:54 ET More on Amgen Amgen, Inc. (AMGN) Q1 2024 Earnings Call Transcript Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet Amgen: I Prefer To Chase Value And Dividends Biggest stock movers today: WOW, AAPL, SQ, and more Amge...
2024-05-02 14:31:50 ET More on Novartis, Novartis AG, etc. Novartis AG (NVS) Q1 2024 Earnings Call Transcript Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis AG 2024 Q1 - Results - Earnings Call Presentation Novartis to b...
First BTK inhibitor to show favorable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in comb...
2024-05-01 14:41:05 ET Summary Eli Lilly and Company's revenue for the first quarter of 2024 fell short of analysts' expectations, but the company exceeded forecasts on the bottom line. Sales of the company's obesity and diabetes drugs, particularly Mounjaro and Zepbound, saw sign...
New data for TEZSPIRE and BREZTRI demonstrate AstraZeneca’s innovation and commitment to transform care in COPD AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Socie...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC Company Name:
AZN Stock Symbol:
NYSE Market:
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its ...
Tuesday, AstraZeneca Plc (NASDAQ:AZN) announced topline data from the CAPItello-290 Phase 3 trial for Truqap (capivasertib) in combinatio...
Sunday, Nurix Therapeutics Inc (NASDAQ:NRIX) announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Br...